Search

Your search keyword '"Chang, Sam S."' showing total 827 results
Start Over Author "Chang, Sam S." Search Limiters Peer Reviewed
827 results on '"Chang, Sam S."'

2. Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) study: a pragmatic, prospective multicenter observational cohort study of recurrent high-grade non-muscle invasive bladder cancer

Author

Gore, John L., Wolff, Erika M., Comstock, Bryan A., Follmer, Kristin M., Nash, Michael G., Basu, Anirban, Chisolm, Stephanie, MacLean, Douglas B., Lee, Jenney R., Lotan, Yair, Porten, Sima P., Steinberg, Gary D., Chang, Sam S., Gilbert, Scott M., Kessler, Larry G., and Smith, Angela B.

Published
2023
Full Text
View/download PDF

8. Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non–muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis

Author

Kamat, Ashish M., Lerner, Seth P., O’Donnell, Michael, Georgieva, Mihaela V., Yang, Min, Inman, Brant A., Kassouf, Wassim, Boorjian, Stephen A., Tyson, Mark D., Kulkarni, Girish S., Chang, Sam S., Konety, Badrinath R., Svatek, Robert S., Balar, Arjun, and Witjes, J. Alfred

Published
2020
Full Text
View/download PDF

16. Intravesical oncolytic virotherapy and immunotherapy for non‐muscle‐invasive bladder cancer mouse model.

Author

Smelser, Woodson W., Wang, Jian, Ogden, Kristen M., Chang, Sam S., and Kirschner, Austin N.

Subjects
UROTHELIUM, ONCOLYTIC virotherapy, CANCER invasiveness, REGULATORY T cells, MYELOID-derived suppressor cells, BLADDER cancer
Abstract

Objectives: To test if intravesical instillation of both an anti‐programmed cell death protein 1 (PD‐1) inhibitor and an oncolytic reovirus would demonstrate a greater effect than either treatment alone, as non‐muscle‐invasive bladder cancer that is refractory to intravesical bacillus Calmette–Guérin can be treated by systemic anti‐PD‐1 immunotherapy and we previously demonstrated improved overall survival (OS) with six once‐weekly instillations of intravesical anti‐PD‐1 in a murine model. Materials and Methods: Using an orthotopic syngeneic C3H murine model of MBT2 urothelial bladder cancer, groups of 10 mice were compared between no treatment, intravesical anti‐PD‐1, intravesical oncolytic reovirus, or intravesical reovirus + anti‐PD‐1. A single intravesical treatment session was given. The primary outcome was OS, and the secondary outcomes included long‐term immunity and tumour–immune profile. Results: With a median follow‐up of 9 months, all mice that received no treatment died with a median survival of 41 days, while the comparison median OS was not reached for reovirus (hazard ratio [HR] 14.4, 95% confidence interval [CI] 3.9–32.6; P < 0.001), anti‐PD‐1 (HR 28.4, 95% CI 7.0–115.9; P < 0.001), and reovirus + anti‐PD‐1 (HR 28.4, 95% CI 7.0–115.9; P < 0.001). Monotherapy with anti‐PD‐1 or reovirus demonstrated no significant differences in survival (P = 0.067). Mass cytometry showed that reovirus + anti‐PD‐1 treatment enriched monocytes and decreased myeloid‐derived suppressor cells, generating an immuno‐responsive tumour microenvironment. Depletion of CD8+ T cells eliminated the survival advantage provided by the intravesical treatment. Conclusions: Treatment of murine orthotopic bladder tumours with a single instillation of intravesical reovirus, anti‐PD‐1 antibody, or the combination confers superior survival compared to controls. Tumour–immune microenvironment differences indicated myeloid‐derived suppressor cells and CD8+ T cells mediate the treatment response. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

17. Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer

Author

Reddy, Opal L., Cates, Justin M., Gellert, Lan L., Crist, Henry S., Yang, Zhaohai, Yamashita, Hironobu, Taylor, John A., III, Smith, Joseph A., Jr., Chang, Sam S., Cookson, Michael S., You, Chaochen, Barocas, Daniel A., Grabowska, Magdalena M., Ye, Fei, Wu, Xue-Ru, Yi, Yajun, Matusik, Robert J., Kaestner, Klaus H., Clark, Peter E., and DeGraff, David J.

Published
2015
Full Text
View/download PDF

22. Alvimopan, a Peripherally Acting μ-Opioid Receptor Antagonist, is Associated with Reduced Costs after Radical Cystectomy: Economic Analysis of a Phase 4 Randomized, Controlled Trial

Author

Kauf, Teresa L., Svatek, Robert S., Amiel, Gilad, Beard, Timothy L., Chang, Sam S., Fergany, Amr, Karnes, R. Jeffrey, Koch, Michael, O'Hara, Jerome, Lee, Cheryl T., Sexton, Wade J., Slaton, Joel W., Steinberg, Gary D., Wilson, Shandra S., Techner, Lee, Martin, Carolyn, Moreno, Jessica, and Kamat, Ashish M.

Published
2014
Full Text
View/download PDF

37. Effects of Specialist Palliative Care for Patients Undergoing Major Abdominal Surgery for Cancer: A Randomized Clinical Trial.

Author

Shinall Jr, Myrick C., Martin, Sara F., Karlekar, Mohana, Hoskins, Aimee, Morgan, Ellis, Kiehl, Amy, Bryant, Patsy, Orun, Onur M., Raman, Rameela, Tillman, Benjamin F., Hawkins, Alexander T., Brown, Alaina J., Bailey, Christina E., Idrees, Kamran, Chang, Sam S., Smith Jr, Joseph A., Tan, Marcus C. B., Magge, Deepa, Penson, David, and Ely, E. Wesley

Published
2023
Full Text
View/download PDF

38. Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO Guideline.

Author

Coleman, Jonathan A., Clark, Peter E., Bixler, Brooke R., Buckley, David I., Chang, Sam S., Chou, Roger, Hoffman-Censits, Jean, Kulkarni, Girish S., Matin, Surena F., Pierorazio, Phillip M., Potretzke, Aaron M., Psutka, Sarah P., Raman, Jay D., Smith, Angela B., and Smith, Laura

Subjects
TRANSITIONAL cell carcinoma, EXECUTIVES, LYMPHADENECTOMY, DIAGNOSIS, MUCOSITIS, ADJUVANT chemotherapy
Abstract

Purpose: The purpose of this guideline is to provide a useful reference on the effective evidence-based diagnoses and management of non-metastatic upper tract urothelial carcinoma (UTUC). Materials/Methods: The Pacific Northwest Evidence-based Practice Center of Oregon Health & Science University (OHSU) team conducted searches in Ovid MEDLINE (1946 to March 3rd, 2022), Cochrane Central Register of Controlled Trials (through January 2022), and Cochrane Database of Systematic Reviews (through January 2022). The searches were updated August 2022. When sufficient evidence existed, the body of evidence was assigned a strength rating of A (high), B (moderate), or C (low) for support of Strong, Moderate, or Conditional Recommendations. In the absence of sufficient evidence, additional information is provided as Clinical Principles and Expert Opinions (Table 1). Results: This Guideline provides updated, evidence-based recommendations regarding diagnosis and management of non-metastatic UTUC including risk stratification, surveillance and survivorship. Treatments discussed include kidney sparing management, surgical management, lymph node dissection (LND), neoadjuvant/adjuvant chemotherapy and immunotherapy. Conclusion: This standardized guideline seeks to improve clinicians' ability to evaluate and treat patients with UTUC based on available evidence. Future studies will be essential to further support these statements for improving patient care. Updates will occur as the knowledge regarding disease biology, clinical behavior and new therapeutic options develop. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

39. Prognostic factors and outcomes in primary urethral cancer: results from the international collaboration on primary urethral carcinoma

Author

Gakis, Georgios, Morgan, Todd M., Efstathiou, Jason A., Keegan, Kirk A., Mischinger, Johannes, Todenhoefer, Tilman, Schubert, Tina, Zaid, Harras B., Hrbacek, Jan, Ali-El-Dein, Bedeir, Clayman, Rebecca H., Galland, Sigolene, Olugbade, Jr., Kola, Rink, Michael, Fritsche, Hans-Martin, Burger, Maximilian, Chang, Sam S., Babjuk, Marko, Thalmann, George N., Stenzl, Arnulf, and Daneshmand, Siamak

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results